Drug intelligence / Profile preview

DWJ1695

Development stage: Preclinical
Lead developer: Daewoong Pharmaceutical
Modality: Peptides
Administration: Subcutaneous

Overview

DWJ1695 is a long-acting injectable formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Daewoong Pharmaceutical. The drug utilizes Daewoong's proprietary SmartDepot technology to enable a sustained release profile, allowing for dosing intervals of one to two months. It is primarily being developed for the treatment of obesity, aiming to provide a more convenient alternative to existing daily or weekly injectable GLP-1 therapies by significantly reducing the frequency of administration.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on DWJ1695.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1695.

Explore the full profile